Creating Defensible Financial Models in Biotech: A Strategic Imperative

In the high-stakes world of biotech and pharmaceutical transactions, credibility is paramount. Investors, strategic partners, and regulators expect financial models that are not only realistic but also defendable under scrutiny. A strong financial model goes beyond just numbers — it provides a comprehensive picture of risk, return, and growth potential.

Click Here

Defensible Financial Models Require Experience

At SVI Consulting Group, we specialize in developing financial models that withstand rigorous due diligence processes, offering your partners confidence in the viability of your assets.

SVI’s Expertise in Financial Modeling

With years of experience in portfolio management, investment analysis, and biotech transactions, SVI brings deep expertise to the table. Our approach ensures your financial models are thorough, transparent, and aligned with real-world market dynamics.

Risk-Adjusted Forecasts
We go beyond basic projections. Our risk-adjusted Net Present Value (NPV) models incorporate competitive threats, regulatory hurdles, market fluctuations, and product lifecycle considerations. This comprehensive approach results in models that provide a realistic outlook on the financial viability of your assets.

Scenario Planning
SVI understands that the biotech and pharmaceutical markets are dynamic and unpredictable. We incorporate scenario planning into our financial models, helping you and your potential partners understand how your asset would perform under different market conditions, competitor actions, and regulatory outcomes.

Case Study: Saving Over $100M Through Rigorous Analysis

One of our clients, a biotech company in the process of acquiring a promising asset, engaged us to conduct due diligence on the financial forecasts provided by the seller. Our review uncovered that the seller’s projections were overly optimistic and based on assumptions that were unlikely to materialize. This led our client to reconsider the acquisition, ultimately saving them over $100M and avoiding a high-risk investment. Instead, they directed their focus toward a product that was a better strategic fit, ensuring a more favorable outcome.

Building Investor Confidence

For startups and early-stage biotech companies, creating a credible financial model can be the difference between securing investment and losing out. SVI helps you build models that inspire confidence, providing potential investors and partners with the transparency and rigor they require to make informed decisions.

Tailored to
Your Needs

A one-size-fits-all model fails to capture the unique value of your asset. We customize our financial analysis to align with your specific strategic objectives—whether you are preparing for a new funding round, negotiating a partnership, or evaluating an M&A opportunity. Our models are built to reflect your technology, development stage, and target market, not a generic industry template.

Conclusion: Ensuring Credibility & Success

In an industry where diligence and precision are non-negotiable, having defensible financial models is key to securing successful partnerships and investments. At SVI Consulting Group, our expertise in financial modeling ensures that your projections are credible, comprehensive, and aligned with market realities.

Ready to Build Defensible Financial Models?

If you need financial models that stand up to scrutiny and help secure successful biotech transactions, contact SVI Consulting Group today. Let us provide you with the rigorous analysis and credible projections that will drive your success